Becton Dickinson stock (US0718131099): ownership moves draw focus as Wall Street stays cautious

Becton Dickinson shares traded little changed on the NYSE on 06/01/2026 as new filings showed diverging institutional moves, with Clear Harbor Asset Management sharply increasing its position while Första AP-fonden reduced its stake, against a backdrop of a consensus Hold rating on the US medical technology group.

Becton Dickinson shares were broadly steady on the New York Stock Exchange on 06/01/2026, as fresh US regulatory filings highlighted contrasting institutional moves in the medical technology group while Wall Street consensus remains cautious on the stock.

According to a MarketBeat summary of a recent Form 13F filing, Clear Harbor Asset Management LLC increased its holdings in Becton, Dickinson and Company by 371.5% in the fourth quarter of the last reported year, signaling renewed confidence from that US-based institutional investor in the United States-listed healthcare supplier.

In the same batch of ownership disclosures cited by MarketBeat on 06/01/2026, Första AP-fonden, one of Sweden’s national pension funds, was reported to have reduced its position in Becton Dickinson, underlining that not all long-term holders are moving in the same direction on the US stock.

The company’s shares are primarily listed on the NYSE under the ticker BDX, with trading in US dollars, and the stock is part of the large-cap US healthcare universe that many benchmarked US equity portfolios track or reference through the S&P 500 and related indices.

Based on data compiled by MarketBeat as referenced in the 06/01/2026 note, seven analysts rate Becton Dickinson a Buy, eight rate it Hold and one has a Sell recommendation, resulting in an overall consensus rating of Hold and an average 12-month price target of USD 183.64.

As of 06/01/2026, Becton Dickinson’s share price on US markets remained close to recent levels reported by live-quote services such as Moneycontrol, which track intraday moves in BDX and provide investors in and outside the United States with realtime data and basic company information.

For German investors, Becton Dickinson is also available via off-exchange trading platforms such as Tradegate or Frankfurt certificates, typically quoted in euros and referencing the NYSE line as the underlying, providing a bridge from the US home market into the broader European retail-investor universe.

The latest institutional holdings updates described by MarketBeat also noted that other investors, including United Bank, had adjusted their exposure to Becton Dickinson in recent quarters, suggesting that professional portfolio managers are actively rebalancing positions in the medical technology name within diversified equity strategies.

The stock’s subdued reaction on 06/01/2026 indicates that, at least on that trading day, the mixed ownership changes and stable analyst consensus were largely anticipated or already reflected in the United States share price for BDX.

The company continues to file its financial statements and material disclosures with the US Securities and Exchange Commission, and investors typically track these primary filings alongside earnings releases and investor-day presentations to reassess their view on the stock over time.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Becton Dickinson
• Sector/industry: Medical technology and healthcare equipment
• Headquarters/country: Franklin Lakes, United States
• Core markets: North America, Europe, Asia-Pacific and other international healthcare markets
• Key revenue drivers: Medical segment products, Life Sciences solutions and Interventional segment devices
• Home exchange/listing venue: New York Stock Exchange (BDX)
• Trading currency: USD

Becton Dickinson: core business model

Becton Dickinson operates as a diversified US-based medical technology group that designs and supplies devices, consumables and diagnostic equipment used across hospitals, laboratories and outpatient settings, with sales driven mainly by recurring demand for medical supplies and integrated solutions in its Medical, Life Sciences and Interventional segments.

What banks and research houses say about Becton Dickinson

Recent data compiled by MarketBeat and cited on 06/01/2026 show that coverage of Becton Dickinson by Wall Street and other research houses currently aggregates to seven Buy ratings, eight Hold ratings and one Sell recommendation, leading to an overall consensus Hold stance on the US-listed stock alongside a mean 12-month price target of USD 183.64.

These aggregated figures indicate that while several banks and brokers see upside potential in BDX within the United States healthcare equipment sector, a slightly larger group prefers a more neutral positioning, which is consistent with the relatively muted share-price reaction to the latest institutional ownership changes reported in early June 2026.

Conclusion

The steady trading in Becton Dickinson shares on the NYSE on 06/01/2026, despite sizable shifts in positions by individual institutional investors such as Clear Harbor Asset Management and Första AP-fonden, suggests that the broader US equity market has largely digested the latest ownership data.

At the same time, the current analyst balance of seven Buys, eight Holds and one Sell with an average target of USD 183.64 underscores a cautious but engaged research backdrop that leaves room for renewed debate as upcoming earnings releases, regulatory milestones or strategic updates shape the narrative around the US medical technology group.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.